{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T01:34:49Z","timestamp":1781314489652,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jacadv.2024.101524","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T14:51:12Z","timestamp":1740581472000},"page":"101524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Finerenone Efficacy in Patients with Chronic Kidney Disease, Type 2 Diabetes, and Anemia in FIDELITY"],"prefix":"10.1016","volume":"4","author":[{"given":"Ajay K.","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Ruilope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo E.","family":"Farjat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef M.K.","family":"Farag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2024.101524_bib1","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2147\/CLEP.S259648","article-title":"Risk of anemia in patients with newly identified chronic kidney disease - a population-based cohort study","volume":"12","author":"Vestergaard","year":"2020","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.jacadv.2024.101524_bib2","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jacadv.2024.101524_bib3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.5527\/wjn.v5.i4.358","article-title":"Diabetes mellitus increases the prevalence of anemia in patients with chronic kidney disease: a nested case-control study","volume":"5","author":"Loutradis","year":"2016","journal-title":"World J Nephrol"},{"key":"10.1016\/j.jacadv.2024.101524_bib4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.ajkd.2017.09.026","article-title":"Update on anemia in ESRD and earlier stages of CKD: Core Curriculum 2018","volume":"71","author":"Fishbane","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"10.1016\/j.jacadv.2024.101524_bib5","first-page":"67","article-title":"Anaemia, diabetes and chronic kidney disease: where are we now?","volume":"38","author":"Stevens","year":"2012","journal-title":"J\u00a0Ren Care"},{"key":"10.1016\/j.jacadv.2024.101524_bib6","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12882-022-02778-8","article-title":"Epidemiology and outcomes in patients with anemia of CKD not on dialysis from a large US healthcare system database: a retrospective observational study","volume":"23","author":"Lamerato","year":"2022","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jacadv.2024.101524_bib7","first-page":"147","article-title":"Anemia and clinical outcomes in patients with non-dialysis dependent or dialysis dependent severe chronic kidney disease: a Danish population-based study","volume":"33","author":"Toft","year":"2020","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.jacadv.2024.101524_bib8","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2024.101524_bib9","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Dr\u00fceke","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2024.101524_bib10","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1053\/j.ajkd.2006.02.170","article-title":"Effect of early correction of anemia on the progression of CKD","volume":"47","author":"Rossert","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacadv.2024.101524_bib11","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in patients with anemia and non-dialysis-dependent CKD","volume":"384","author":"Chertow","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2024.101524_bib12","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the treatment of anemia in patients not undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2024.101524_bib13","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2024.101524_bib14","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2024.101524_bib15","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2024.101524_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects","volume":"18","author":"Barrera-Chimal","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jacadv.2024.101524_bib18","first-page":"29","article-title":"Inhibition of RAS in diabetic nephropathy","volume":"8","author":"Yacoub","year":"2015","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1016\/j.jacadv.2024.101524_bib19","first-page":"321","article-title":"Aldosterone receptor antagonists: current perspectives and therapies","volume":"9","author":"Guichard","year":"2013","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jacadv.2024.101524_bib20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000507272","article-title":"Competing effects of renin angiotensin system blockade and sodium-glucose cotransporter-2 inhibitors on erythropoietin secretion in diabetes","volume":"51","author":"Marathias","year":"2020","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jacadv.2024.101524_bib21","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3389\/fphys.2019.01108","article-title":"Chronic kidney disease as a risk factor for heart failure with preserved ejection fraction: a focus on microcirculatory factors and therapeutic targets","volume":"10","author":"van de Wouw","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.jacadv.2024.101524_bib22","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1093\/cvr\/cvac007","article-title":"Smooth muscle mineralocorticoid receptor as an epigenetic regulator of vascular aging","volume":"118","author":"Ibarrola","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacadv.2024.101524_bib23","article-title":"The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials","volume":"11","author":"Arici","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jacadv.2024.101524_bib24","doi-asserted-by":"crossref","first-page":"12592","DOI":"10.3390\/ijms232012592","article-title":"Importance of micromilieu for pathophysiologic mineralocorticoid receptor activity-when the mineralocorticoid receptor resides in the wrong neighborhood","volume":"23","author":"Griesler","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacadv.2024.101524_bib25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ajh.2007.53","article-title":"Effects of the renin-angiotensin system blockade on hemoglobin levels in type 2 diabetic patients with chronic kidney disease","volume":"21","author":"Inoue","year":"2008","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jacadv.2024.101524_bib26","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/sj.ki.5002746","article-title":"The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes","volume":"73","author":"Mohanram","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacadv.2024.101524_bib27","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3109\/00365519009089178","article-title":"Effect of enalapril on haemoglobin and serum erythropoietin in patients with chronic nephropathy","volume":"50","author":"Kamper","year":"1990","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.jacadv.2024.101524_bib28","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3389\/fphar.2018.01131","article-title":"Finerenone attenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by a reduction in oxidative stress","volume":"9","author":"Gonzalez-Blazquez","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacadv.2024.101524_bib29","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","article-title":"Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress","volume":"69","author":"Lattenist","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.jacadv.2024.101524_bib30","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1113\/jphysiol.2010.195057","article-title":"Regulation of erythropoietin production","volume":"589","author":"Jelkmann","year":"2011","journal-title":"J\u00a0Physiol"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X24008044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X24008044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T03:17:11Z","timestamp":1768965431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X24008044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2772963X24008044"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2024.101524","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Finerenone Efficacy in Patients with Chronic Kidney Disease, Type 2 Diabetes, and Anemia in FIDELITY","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2024.101524","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"101524"}}